Optimization of Transfection Efficiency of Lipid Nanoparticles Using Various Statistical Experimental Design Methods
Project no. 32192 · Status: Kapanmış (Yayın bekleniyor) · 2024
Summary
<p>Nonviral drug delivery systems, such as lipid nanoparticles (LNPs), significantly improve the solubility, bioavailability, pharmacokinetic parameters, intestinal absorption, skin penetration, and ocular residence time of drugs, helping the molecule cross physiological barriers and reducing side effects. They aid in endocytosis and endosomal escape by protecting mRNA from degradation. Adjuvants can be added to LNPs, allowing them to aid in immune activation and potentially the adaptation of the immune response. Furthermore, LNPs can be targeted to specific cell types by equipping their surfaces with specific ligands (Dhiman et al. 2021). With the use of biocompatible and biodegradable lipids, LNPs have attracted great interest in recent years and have become a prominent technology (Haider et al. 2020).</p><p>Lipid particle drug delivery systems can be fundamentally classified as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). Within the scope of our study, experiments with Solid Lipid Nanoparticles (SLNs) are planned to be carried out.</p><p>The variations in the type, ratios, and formulation methods of the components for the production of SLNs lead to the creation of a large sample area. Therefore, a method that allows for systematic analysis should be applied before proceeding to the experimental stage. In factorial design, the appropriate sample size is determined by selecting various factors and levels for the analysis of dependent and independent variables. The main goal is to obtain the highest level of output with the minimum number of data while increasing efficiency and reducing labor and cost (Kumar et al. 2017; Yasir and Sara 2013).</p><p>For this purpose, while developing SLN formulations in the study, 3 different methods will be used from statistical experimental design models: Box-Behnken, Taguchi, and central composite design, and the best method will be determined by comparing the results. In addition, the complexes formed by the determined optimum SLN formulation with plasmid DNA will be characterized and these complexes will be evaluated in terms of transfection efficiency.</p>